NASDAQ: PATH       Uipath Inc Cl A
Last Price Today's Change   Day's Range   Trading Volume
18.24   +0.31 (1.73%)  18.19 - 19.53  20,177,700


Avg Volume (4 weeks):13,105,600
4 Weeks Range:12.65 - 19.53
4 Weeks Price Volatility (%):
52 Weeks Range:10.74 - 21.69
52 Weeks Price Volatility (%):
Average Price Target: 17.00
Price Target Upside/Downside: -1.24


No recent Headlines for this stock.

Business Background

NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

  Be the first to like this.
sammofee ada potential
21/08/2021 9:40 PM
Wong137 Shares of Uipath (NYSE: ) are down nearly 15% in premarket trading Thursday after the company released a weaker-thanexpected Q1 revenue forecast.
The software maker reported Q4 adjusted EPS of 5c, well above the analyst consensus of 2.6c per share. Total revenue in the quarter
came in at $289.7 million.
For the first quarter, UiPath expects revenue in the range of $223 million to $225 million, missing the consensus estimates of $246.4
million. The company expects Q1 adjusted operating loss in the range of $25 million to $30 million.
"We have built a global business that serves customers in more than 115 countries, including countries across eastern Europe and
Russia," said the company's CEO Daniel Dines.
Looking ahead, we feel confident in our market-leading position in automation and prospects for future growth at scale but believe it is
prudent at this time to factor both our European exposure and go-to-market leadership transition into the financial outlook we are
providing this afternoon.
Credit Suisse analyst Phil Winslow believes PATH's guidance reflects significant conservatism. The analyst slashed the price target to
$57.50 from the prior $75.00.
To further frame the conservatism in terms of new vs. expansion business, FY2023 ARR guidance excluding headwinds would imply
$0 ARR contribution from new customers and DBNRR declining from 145% to ~134% "despite maintaining a best-in-class range vs.
153% exiting FY2020. We reiterate our thesis that the market opportunity in terms of global automatable wages is both sizable and
largely untapped, we believe that UiPath, with the only purpose-built, end-to-end hyperautomation platform, is leading the paradigm
shift toward the fully-automated enterprise," Winslow said in a client note.
Cowen analyst Bryan Bergin sees many moving parts in the PATH story after EPS.
31/03/2022 11:01 AM

I3 Messenger
Individual or Group chat with anyone on I3investor

6687  2946  917  902 

Top 10 Active Counters
 TSLA 213.97+6.45 
 SQQQ 21.74-0.48 
 TQQQ 36.82+0.81 
 T 15.21-0.60 
 UTRS 0.293+0.093 
 MMV 2.04+1.09 
 SPY 427.92+6.10 
 YJ 0.32+0.108 
 PLTR 14.52-0.02 
 BAC 28.71+0.93